Article By:
Don Dion
Wednesday, October 26, 2016 1:02 AM EDT
Ra Pharmaceuticals filed its S-1/A with the Securities and Exchange Commission, announcing its intention to offer 5.8 million shares at an expected price range of $12 to $14.
In this article: MRK, NVS, ALNY, RARX